Type 1 Diabetes Patients Live Insulin-Free for First Time in Breakthrough Trial

Revolutionary immunosuppression approach enables safe islet transplantation

For people with Type 1 diabetes, the dream of freedom from daily insulin injections has moved closer to reality. A clinical trial at the University of Chicago Medicine has successfully enabled patients to achieve insulin independence following islet cell transplantation, using a revolutionary immunosuppressive approach that avoids the serious side effects of traditional regimens.

The breakthrough centers on tegoprubart, an immunosuppressive protocol that prevents rejection of transplanted insulin-producing islet cells without the kidney damage and other severe complications associated with current anti-rejection medications. Patients in the trial have maintained normal blood sugar levels without insulin injections, while avoiding the nephrotoxicity that has limited islet transplantation as a treatment option.

This represents a potential paradigm shift for Type 1 diabetes treatment — moving from lifetime management to potential cure, while eliminating the trade-off between diabetes complications and immunosuppression side effects.

Key Facts

• Patients achieved insulin independence after islet transplantation
• No rejection episodes observed with tegoprubart protocol
• Eliminates nephrotoxicity of traditional immunosuppressive drugs
• Excellent tolerability compared to standard regimens
• Source: University of Chicago Medicine clinical trial, HCP Live publication